Gamma-synuclein (SNCG), a 127-amino-acid protein belonging to the synuclein family, is predominantly expressed in the nervous system and epithelial tissues. It regulates cytoskeletal dynamics, cell proliferation, and neurotransmitter release under physiological conditions. Dysregulated SNCG expression is linked to neurodegenerative diseases and multiple cancers, where it promotes tumor invasion and metastasis by modulating signaling pathways. Emerging evidence indicates its role as an oncogenic driver, making it a potential therapeutic target. SNCG interacts with VEGFR1 to enhance vascular endothelial growth factor (VEGF)-mediated signaling, facilitating angiogenesis and tumor progression.To detect the activity of recombinant SNCG, a functional ELISA assay was performed to evaluate the interaction between recombinant human SNCG and recombinant human VEGFR1.Briefly, biotin-linked SNCG were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100µl were then transferred to VEGFR1-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST 3 times and incubation with Streptavidin-HRP for 30min, then wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µl stop solution to the wells and read at 450nm immediately. The binding activity of SNCG and VEGFR1 was shown in Figure 1, the EC50 for this effect is 0.15147µg/mL.